The Influence of Prior Therapy on the Success of Trabeculectomy

Lavin, Michael; Wormald, Richard; Migdal, Clive; Hitchings, Roger A.

doi:10.1001/archopht.1990.01070130045027

Cited by 292 publications

(129 citation statements)

References 14 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…[46][47][48] Our study found nearly statistical significance for this risk factor for failure. The literature on the adverse effects of topical antiglaucoma medication on the outcome of filtration surgery dates from the era before the routine intraoperative use of antimetabolites.…”

Section: Eyesupporting

confidence: 53%

Long-term outcomes and risk factors for failure with the EX-press glaucoma drainage device

Mariotti

Dahan

Nicolai

et al. 2013

Eye

View full text Add to dashboard Cite

Purpose To report on the long-term outcomes and risk factors for failure with the EX-PRESS shunt implanted under a scleral flap. Results Two hundred and forty-eight eyes of 211 consecutive patients were included. The mean IOP was reduced from 27.63 ± 8.26 mm Hg preoperatively (n ¼ 248) to 13.95 ± 2.70 mm Hg at 5 years (n ¼ 95). The mean follow-up was 3.46 ± 1.76 years. Complete and qualified success rates decreased gradually from 83% and 85% at 1 year to 57% and 63% at 5 years follow-up, respectively. The risk factors for failure were diabetes, non-Caucasian race, and previous glaucoma surgery. Complete success rates of diabetic patients and non-Caucasian patients decreased from 63% and 75% at 1 year to 42% and 40% at 5 years follow-up, respectively. Conclusions EX-PRESS success rates decrease over time but compare favourably with trabeculectomy literature data. The main identifiable risk factors for failure are diabetes, non-Caucasian race, and previous glaucoma surgery.

show abstract

Section: Eyesupporting

confidence: 53%

Long-term outcomes and risk factors for failure with the EX-press glaucoma drainage device

Mariotti

Dahan

Nicolai

et al. 2013

Eye

View full text Add to dashboard Cite

show abstract

“…Various reasons have been adduced for this. Lavin et al 28 found that filtering surgery was more successful in patients who had received an average of only 2 weeks of preoperative medical treatment than in patients who had received at least 1 year of antiglaucoma treatment. Broadway et al 29 reported that long-term topical medication caused a decrease in goblet cell density but an increase in fibroblasts, macrophages, and mast cells in the substantia propria and an increase in macrophages and lymphocytes in the epithelium.…”

Section: Discussionmentioning

confidence: 99%

Post-operative complication of trabeculectomy in Ibadan, Nigeria: outcome of 1-year follow-up

Ashaye

Komolafe

2007

Eye

View full text Add to dashboard Cite

Objective To describe the post-operative complications reported in patients who had trabeculectomy with and without antimetabolite in UCH, Ibadan between 1999 and 2003 and the success rate achieved in term of the post-operative intraocular pressure (IOP). Methods A retrospective study of the records of glaucoma patients who had trabeculectomy between 1999 and 2003 and had follow-up in UCH Ibadan eye clinic for a minimum of 1 year was carried out. Results Seventy-six out of 171 eyes that had trabeculectomy during the period were reviewed. Mean age of patients was 49.4 years. The mean preoperative IOP was 31.8 mm Hg. Success rate of 79.4% was achieved in term of IOP control at a year of follow-up. The most frequent early post-operative complication was shallow AC (13 eyes; 17.1%) while late complication was elevated IOP (21 eyes; 27.6%). Others were encapsulated bleb 7.9% and hyphema 3.9%. There was no significant difference in the complication rate in those who had intraoperative antimetabolite (5-fluorouracil) when compared with those operated without antimetabolite. Conclusion Guarded filtration surgery is effective in controlling IOP. Most of the complications noted were transient and not visually threatening.

show abstract

“…Long term topical medication, however, seems to have a negative influence on surgery (Richter et al 1988;Lavin et al 1990;Broadway et al 1994). A laser trabeculoplasty secondary to maximal medical treatment will result in an extended duration of combined topical therapy before subsequent operation may become necessary, with increased risk of encapsulation (Broadway et al 1994).…”

Section: Discussionmentioning

confidence: 99%

The medium and long‐term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open angle glaucoma

Odberg

Sandvik

1999

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

Results: The probability of treatment success (no medication required) was for chronic open angle glaucoma 77% after 2 years, 67% after 5 years and 67% after 8 years. Corresponding numbers for pseudoexfoliation glaucoma were 80%, 54% and 36%. Prelaser IOP higher than 31 mmHg, pretreatment visual field defect and sparse pigmentation of the trabecular meshwork were independent predictors of failure. Conclusion: Primary argon laser trabeculoplasty gives a long-lasting and favourable effect in chronic open angle glaucoma where 2/3 of the eyes still managed without additional medication for 8 years. The success in pseudoexfoliation glaucoma was even higher the first 3 years, and kept above 50% for 5 years. This makes laser a valuable option as first choice of therapy in glaucoma.Key words: open angle glaucoma -pseudoexfoliation glaucoma -argon laser trabeculoplastyprimary treatment -long-term results -quality of life.

show abstract

The Influence of Prior Therapy on the Success of Trabeculectomy

Cited by 292 publications

References 14 publications

Long-term outcomes and risk factors for failure with the EX-press glaucoma drainage device

Long-term outcomes and risk factors for failure with the EX-press glaucoma drainage device

Post-operative complication of trabeculectomy in Ibadan, Nigeria: outcome of 1-year follow-up

The medium and long‐term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open angle glaucoma

Contact Info

Product

Resources

About